Neurizon Therapeutics Limited has released a press release.
Extension Study Begins, Analysis Suggests Survival Benefit
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Ethics Committee Approval for Open-Label MND Extension Study
- FDA Provides Clear Feedback for ODD Approval
- PharmAust Partners with Berry Consultants for MND Phase 2/3
- FDA Grants PharmAust Pre-IND Meeting
- FightMND Invites PharmAust to Apply for Phase 2/3 Funding
Later from Neurizon Therapeutics
- FDA Outlines Pathway to Accelerated Approval for MPL in MND
- PharmAust Forms World-Class Scientific Advisory Board
- Presentation - Phase 1 Top-Line Results
- Positive Phase 1 MEND Study Top-Line Results
- Appendix 4D & Half-Year Report
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics